374 related articles for article (PubMed ID: 24674885)
21. CD33 directed bispecific antibodies in acute myeloid leukemia.
Clark MC; Stein A
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101224. PubMed ID: 33279180
[TBL] [Abstract][Full Text] [Related]
22. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
[TBL] [Abstract][Full Text] [Related]
23. CD33 BiTE
Marcinek A; Brauchle B; Rohrbacher L; Hänel G; Philipp N; Märkl F; Strzalkowski T; Lacher SM; Udiljak D; Spiekermann K; Theurich S; Kobold S; Kischel R; James JR; Bücklein VL; Subklewe M
Cancer Immunol Immunother; 2023 Jul; 72(7):2499-2512. PubMed ID: 37041225
[TBL] [Abstract][Full Text] [Related]
24. Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile.
Zeng Z; Roobrouck A; Deschamps G; Bonnevaux H; Guerif S; De Brabandere V; Amara C; Dejonckheere E; Virone-Oddos A; Chiron M; Konopleva M; Dullaers M
Blood Adv; 2024 May; 8(9):2059-2073. PubMed ID: 38266153
[TBL] [Abstract][Full Text] [Related]
25. An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity.
Yeung YA; Krishnamoorthy V; Dettling D; Sommer C; Poulsen K; Ni I; Pham A; Chen W; Liao-Chan S; Lindquist K; Chin SM; Chunyk AG; Hu W; Sasu B; Chaparro-Riggers J; Djuretic I
Mol Ther; 2020 Mar; 28(3):889-900. PubMed ID: 31981494
[TBL] [Abstract][Full Text] [Related]
26. MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis.
van Loo PF; Hangalapura BN; Thordardottir S; Gibbins JD; Veninga H; Hendriks LJA; Kramer A; Roovers RC; Leenders M; de Kruif J; Doornbos RP; Sirulnik A; Throsby M; Logtenberg T; Dolstra H; Bakker ABH
Expert Opin Biol Ther; 2019 Jul; 19(7):721-733. PubMed ID: 31286786
[No Abstract] [Full Text] [Related]
27. Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia.
Walter RB
Expert Rev Hematol; 2014 Jun; 7(3):317-9. PubMed ID: 24617311
[TBL] [Abstract][Full Text] [Related]
28. ImmunoPET, [
Srideshikan SM; Brooks J; Zuro D; Kumar B; Sanchez J; Echavarria Parra L; Orellana M; Vishwasrao P; Nair I; Chea J; Poku K; Bowles N; Miller A; Ebner T; Molnar J; Rosenthal J; Vallera DA; Wong JYC; Stein AS; Colcher D; Shively JE; Yazaki PJ; Hui SK
Clin Cancer Res; 2019 Dec; 25(24):7463-7474. PubMed ID: 31548348
[TBL] [Abstract][Full Text] [Related]
29. The role of CD33 as therapeutic target in acute myeloid leukemia.
Walter RB
Expert Opin Ther Targets; 2014 Jul; 18(7):715-8. PubMed ID: 24750020
[TBL] [Abstract][Full Text] [Related]
30. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
[TBL] [Abstract][Full Text] [Related]
31. A Chemo-enzymatically Linked Bispecific Antibody Retargets T Cells to a Sialylated Epitope on CD43 in Acute Myeloid Leukemia.
Bartels L; de Jong G; Gillissen MA; Yasuda E; Kattler V; Bru C; Fatmawati C; van Hal-van Veen SE; Cercel MG; Moiset G; Bakker AQ; van Helden PM; Villaudy J; Hazenberg MD; Spits H; Wagner K
Cancer Res; 2019 Jul; 79(13):3372-3382. PubMed ID: 31064847
[TBL] [Abstract][Full Text] [Related]
32. A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia.
Hoseini SS; Guo H; Wu Z; Hatano MN; Cheung NV
Blood Adv; 2018 Jun; 2(11):1250-1258. PubMed ID: 29858209
[TBL] [Abstract][Full Text] [Related]
33. Investigational CD33-targeted therapeutics for acute myeloid leukemia.
Walter RB
Expert Opin Investig Drugs; 2018 Apr; 27(4):339-348. PubMed ID: 29534618
[TBL] [Abstract][Full Text] [Related]
34. Fc-engineered anti-CD33 monoclonal antibody potentiates cytotoxicity of membrane-bound interleukin-21 expanded natural killer cells in acute myeloid leukemia.
Mani R; Rajgolikar G; Nunes J; Zapolnik K; Wasmuth R; Mo X; Byrd JC; Lee DA; Muthusamy N; Vasu S
Cytotherapy; 2020 Jul; 22(7):369-376. PubMed ID: 32303428
[TBL] [Abstract][Full Text] [Related]
35. Melanoma cells can be eliminated by sialylated CD43 × CD3 bispecific T cell engager formats in vitro and in vivo.
de Jong G; Bartels L; Kedde M; Verdegaal EME; Gillissen MA; Levie SE; Cercel MG; van Hal-van Veen SE; Fatmawati C; van de Berg D; Yasuda E; Claassen YB; Bakker AQ; van der Burg SH; Schotte R; Villaudy J; Spits H; Hazenberg MD; van Helden PM; Wagner K
Cancer Immunol Immunother; 2021 Jun; 70(6):1569-1581. PubMed ID: 33225419
[TBL] [Abstract][Full Text] [Related]
36. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia.
Kenderian SS; Ruella M; Shestova O; Klichinsky M; Aikawa V; Morrissette JJ; Scholler J; Song D; Porter DL; Carroll M; June CH; Gill S
Leukemia; 2015 Aug; 29(8):1637-47. PubMed ID: 25721896
[TBL] [Abstract][Full Text] [Related]
37. A phase I trial of humanized monoclonal antibody HuM195 (anti-CD33) with low-dose interleukin 2 in acute myelogenous leukemia.
Kossman SE; Scheinberg DA; Jurcic JG; Jimenez J; Caron PC
Clin Cancer Res; 1999 Oct; 5(10):2748-55. PubMed ID: 10537338
[TBL] [Abstract][Full Text] [Related]
38. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.
Chichili GR; Huang L; Li H; Burke S; He L; Tang Q; Jin L; Gorlatov S; Ciccarone V; Chen F; Koenig S; Shannon M; Alderson R; Moore PA; Johnson S; Bonvini E
Sci Transl Med; 2015 May; 7(289):289ra82. PubMed ID: 26019218
[TBL] [Abstract][Full Text] [Related]
39. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.
Al-Hussaini M; Rettig MP; Ritchey JK; Karpova D; Uy GL; Eissenberg LG; Gao F; Eades WC; Bonvini E; Chichili GR; Moore PA; Johnson S; Collins L; DiPersio JF
Blood; 2016 Jan; 127(1):122-31. PubMed ID: 26531164
[TBL] [Abstract][Full Text] [Related]
40. Anti-CD33-antibodies labelled with the alpha-emitter Bismuth-213 kill CD33-positive acute myeloid leukaemia cells specifically by activation of caspases and break radio- and chemoresistance by inhibition of the anti-apoptotic proteins X-linked inhibitor of apoptosis protein and B-cell lymphoma-extra large.
Friesen C; Roscher M; Hormann I; Leib O; Marx S; Moreno J; Miltner E
Eur J Cancer; 2013 Jul; 49(11):2542-54. PubMed ID: 23684782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
